YKL-40 (Chitinase-3-like protein 1)
> YKL-40 as neuroinflammatory biomarker for neurodegeneration: microglial activation, clinical utility in AD, PD, MS, and ALS
Overview
flowchart TD
YKL40["YKL40"] -->|"biomarker for"| Neuroinflammation["Neuroinflammation"]
YKL40["YKL40"] -->|"biomarker for"| Alzheimer_s_disease["Alzheimer's disease"]
style YKL40 fill:#4fc3f7,stroke:#333,color:#000
YKL-40 (also known as Chitinase-3-like protein 1 or CHI3L1) is a 39-kDa secreted glycoprotein belonging to the glycoside hydrolase family 18. Unlike true chitinases which have enzymatic activity, YKL-40 is a chitinase-like protein (CLP) lacking catalytic function but retaining chitin-binding properties. It is produced primarily by activated macrophages, microglia, and astrocytes in the CNS, and serves as a robust marker of neuroinflammatory responses in neurodegenerative diseases["@boncoeur_ykl"].
Unlike [GFAP](/biomarkers/gfap) which reflects astrocyte activation, YKL-40 specifically indicates microglial activation and macrophage infiltration, providing complementary information about the innate immune component of neurodegeneration. CSF and blood YKL-40 are elevated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS, and other neuroinflammatory conditions, making it a versatile inflammatory biomarker["@olsson_ykl"].
Biochemistry
YKL-40 Protein Structure
YKL-40 is a member of the chitinase-like protein family with distinctive structural features[@jensen_ykl]:
...YKL-40 (Chitinase-3-like protein 1)
> YKL-40 as neuroinflammatory biomarker for neurodegeneration: microglial activation, clinical utility in AD, PD, MS, and ALS
Overview
Mermaid diagram (expand to render)
YKL-40 (also known as Chitinase-3-like protein 1 or CHI3L1) is a 39-kDa secreted glycoprotein belonging to the glycoside hydrolase family 18. Unlike true chitinases which have enzymatic activity, YKL-40 is a chitinase-like protein (CLP) lacking catalytic function but retaining chitin-binding properties. It is produced primarily by activated macrophages, microglia, and astrocytes in the CNS, and serves as a robust marker of neuroinflammatory responses in neurodegenerative diseases["@boncoeur_ykl"].
Unlike [GFAP](/biomarkers/gfap) which reflects astrocyte activation, YKL-40 specifically indicates microglial activation and macrophage infiltration, providing complementary information about the innate immune component of neurodegeneration. CSF and blood YKL-40 are elevated in Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS, and other neuroinflammatory conditions, making it a versatile inflammatory biomarker["@olsson_ykl"].
Biochemistry
YKL-40 Protein Structure
YKL-40 is a member of the chitinase-like protein family with distinctive structural features[@jensen_ykl]:
Primary structure:
- 383 amino acids, signal peptide (22 aa) + mature protein (361 aa)
- Molecular weight: 39,638 Da
- Named for its N-terminal YKL sequence and apparent molecular weight
Structural domains:
- TIM barrel fold (glycoside hydrolase family 18) — Similar to true chitinases but with altered active site
- Chitin-binding domain — Enables interaction with extracellular matrix components
- Heparin-binding region — Interacts with proteoglycans and cell surfaces
Key amino acid motifs:
- DXDXE sequence (catalytic acid) — Present but non-functional in YKL-40
- 18 conserved positions compared to active chitinases
- Rationally mutated in studies to prevent substrate binding
Cellular Sources
YKL-40 production in the CNS is restricted to specific cell types[@boncoeur_ykl]:
Microglia — Primary source in neurodegeneration:
- Baseline: Low/undetectable in resting microglia
- Activated: Strong upregulation in pro-inflammatory (M1-like) state
- Regional pattern: Higher in areas of active neurodegeneration
Astrocytes — Secondary source:
- Reactive astrocytes produce YKL-40 in response to inflammatory cytokines
- Particularly elevated in areas of astrogliosis
Macrophages/monocytes — Peripheral contribution:
- Infiltrating macrophages at blood-brain barrier breach points
- Contributes to blood YKL-40 levels
Neurons — Limited expression:
- Not a primary neuronal product
- Some reports of neuronal YKL-40 in specific conditions
Regulation of YKL-40 Expression
Multiple signaling pathways drive YKL-40 upregulation[@boncoeur_ykl]:
- IL-6 family cytokines (IL-6, LIF, CNTF) — Potent inducers via STAT3
- TGF-beta — Moderate induction
- IFN-gamma — Synergizes with IL-6
- Lipopolysaccharide (LPS) — Strong induction via TLR4
- Amyloid-beta — Direct activation of microglial YKL-40 production
Pathophysiological Role
Neuroinflammation in Neurodegeneration
YKL-40 elevation reflects the prominent neuroinflammatory component of neurodegenerative diseases[@boncoeur_ykl]:
Alzheimer's Disease[@olsson_ykl]:
- YKL-40 correlates with amyloid and tau pathology burden
- Reflects microglial activation around amyloid plaques (TREM2-dependent responses)
- Higher levels associated with faster disease progression
- Independent of amyloid/tau biomarkers, providing complementary information
Parkinson's Disease[@huang_ykl]:
- YKL-40 elevated in PD CSF compared to controls
- Correlates with disease severity and duration
- May reflect microglial activation in substantia nigra
- Helps distinguish PD from atypical parkinsonian syndromes
Multiple Sclerosis[@comabella_ykl]:
- YKL-40 is one of the best-validated CSF inflammatory markers in MS
- Elevated during active demyelination
- Predicts conversion from CIS to clinically definite MS
- Higher in progressive MS subtypes
ALS[@beyer_ykl]:
- YKL-40 elevated in ALS CSF, reflecting neuroinflammation
- Correlates with disease progression rate
- May indicate microglial involvement in motoneuron degeneration
- Independent of neurofilament markers
Mechanisms of YKL-40 Release
CSF YKL-40 elevation occurs through[@jensen_ykl]:
Microglial activation — Upregulated YKL-40 secreted into extracellular space
Astrocyte reactivity — Additional source during neuroinflammation
Cell death — Release from activated cells undergoing death
Peripheral spillover — Blood-brain barrier disruption allows plasma leakage
Exosome secretion — YKL-40 packaged in extracellular vesiclesYKL-40 vs GFAP
These two astroimmune biomarkers provide complementary information[@boncoeur_ykl]:
| Feature | YKL-40 | GFAP |
|---------|--------|------|
| Primary cell source | Activated microglia | Reactive astrocytes |
| Specificity | Neuroinflammation | Astrogliosis |
| AD sensitivity | Moderate | High |
| MS sensitivity | High | Moderate |
| PD sensitivity | Moderate | Low |
| ALS sensitivity | Moderate | Low |
Clinical Utility
Alzheimer's Disease
CSF YKL-40 in AD[@sutphen_ykl]:
| Comparison | AUC | Notes |
|------------|-----|-------|
| AD vs CN | 0.75-0.82 | Moderate accuracy |
| AD vs FTD | 0.70-0.76 | Lower than p-tau/tau biomarkers |
| MCI-AD vs stable MCI | 0.72-0.78 | Moderate predictive value |
| AD vs DLB | 0.68-0.74 | Limited discrimination |
YKL-40 provides inflammatory context to amyloid and tau biomarkers but is not suitable as a standalone diagnostic marker.
Prediction of progression[@sutphen_ykl]:
- Higher baseline YKL-40 predicts faster cognitive decline
- Rate of increase correlates with brain atrophy
- Combined with p-tau181 and NfL improves prognostic models
Parkinson's Disease
CSF YKL-40 in PD[@hooton_ykl]:
| Comparison | AUC | Notes |
|------------|-----|-------|
| PD vs CN | 0.72-0.78 | Moderate accuracy |
| PD vs PSP | 0.68-0.74 | Distinguishes some atypical parkinsonisms |
| PD vs MSA | 0.65-0.72 | Limited discrimination |
| PD dementia vs PD | 0.70-0.76 | Associates with cognitive decline |
Multiple Sclerosis
CSF YKL-40 as MS biomarker[@correll_ykl]:
| Comparison | AUC | Notes |
|------------|-----|-------|
| MS vs CN | 0.78-0.85 | Good inflammatory marker |
| MS vs other dementia | 0.70-0.78 | Limited |
| CIS to MS conversion | 0.74-0.80 | Predicts progression |
| Progressive vs relapsing | 0.76-0.82 | Higher in progressive MS |
Clinical applications in MS:
- Risk stratification after first demyelinating event
- Monitoring disease activity and treatment response
- Surrogate marker for intrathecal inflammation
- Prognostic indicator for disability progression
Frontotemporal Dementia
CSF YKL-40 in FTD[@karlsen_ykl]:
- Elevated in FTD-TDP compared to controls
- Higher in FTD than in AD (in some cohorts)
- May help distinguish FTD inflammatory component
- Correlates with disease severity
ALS
CSF YKL-40 in ALS[@zhang_ykl]:
| Comparison | AUC | Notes |
|------------|-----|-------|
| ALS vs CN | 0.75-0.82 | Moderate accuracy |
| ALS vs mimics | 0.70-0.76 | Limited |
| Fast vs slow progression | 0.68-0.74 | Higher in rapid progressors |
Analytical Methods
Immunoassays
YKL-40 is measured using validated immunoassays[@boncoeur_ykl]:
| Platform | Detection | Notes |
|----------|-----------|-------|
| ELISA (commercial kits) | 20-1000 pg/mL | Research standard |
| MSD | 1-1000 pg/mL | Multiplex capability |
| Simoa | 0.1-100 pg/mL | Higher sensitivity |
| Luminex | 10-10000 pg/mL | Flexibility |
Sample Considerations
CSF YKL-40 measurement:
- Minimal contamination from blood allows reliable measurement
- Blood YKL-40 also measurable but peripheral inflammation contributes
- Pre-analytical variables similar to other CSF biomarkers
Cutoff Values
CSF YKL-40 (platform-dependent):
| Concentration | Interpretation | Notes |
|--------------|----------------|-------|
| <100 ng/mL | Normal | Cognitively unimpaired young |
| 100-150 ng/mL | Borderline | Requires clinical correlation |
| >150 ng/mL | Elevated | Indicates neuroinflammation |
Blood YKL-40:
- Higher concentrations than CSF due to peripheral production
- Less specific for CNS pathology
- Useful for systemic inflammatory monitoring
Limitations
Specificity Limitations
YKL-40 is not disease-specific[@boncoeur_ykl]:
- Elevated in multiple neuroinflammatory conditions
- Peripheral inflammation can elevate blood levels
- Cannot distinguish between different inflammatory etiologies
Compared to core AD biomarkers:
- Lower AUC than p-tau181, p-tau217 for AD diagnosis
- Not suitable as standalone diagnostic marker
- Requires interpretation within clinical context
Confounding Factors
| Factor | Effect | Notes |
|--------|--------|-------|
| Age | Increases with normal aging | Age-adjusted cutoffs |
| Peripheral infection | Elevates blood YKL-40 | CNS-specific requires CSF |
| Autoimmune disease | Elevates YKL-40 | Systemic inflammation |
| Trauma | Acute elevation | Recent TBI confounds |
Research Applications
Microglial Activation Imaging
TSPO PET studies show YKL-40 correlates with microglial activation[@victor_ykl]:
- YKL-40 CSF levels correlate with TSPO binding in some regions
- Indicates microglial burden in AD and other conditions
- Complements grey matter atrophy measures
Mechanistic Insights
YKL-40 provides insights into neuroinflammation mechanisms[@brugge_ykl]:
- Direct evidence of microglial activation in human disease
- Temporal relationship with other biomarkers
- Animal models show YKL-40 upregulation in neurodegeneration paradigms
Clinical Trial Applications
In clinical trials[@boncoeur_ykl]:
- Pharmacodynamic marker for anti-inflammatory therapies
- Enrichment biomarker for trials targeting microglia
- Secondary endpoint for immunomodulatory interventions
Summary
YKL-40 is a validated CSF and blood biomarker that specifically reflects microglial activation and neuroinflammation in neurodegenerative diseases. Key points:
- Biochemistry: Chitinase-like protein 1, 39 kDa, produced by activated microglia and astrocytes
- Clinical performance: AUC 0.72-0.82 for AD detection; useful in MS, PD, ALS, FTD
- Cutoff values: CSF >150 ng/mL indicates elevated neuroinflammation
- Clinical utility: Neuroinflammation monitoring, disease progression prediction, clinical trial endpoint
- Strengths: Direct microglial marker, MS diagnostic utility, complements other biomarkers
- Limitations: Non-specific, lower diagnostic accuracy than core AD biomarkers
YKL-40 provides essential information about the neuroinflammatory axis of neurodegeneration that is not captured by amyloid, tau, or axonal markers.
- [Glial Fibrillary Acidic Protein (GFAP)](/biomarkers/gfap) — Astrocyte marker; complements YKL-40
- [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light) — Axonal degeneration; independent of YKL-40
- [Phosphorylated Tau 181 (p-tau181)](/biomarkers/csf-pta181) — Tau pathology; combined with YKL-40
- [Microglial Activation in Neurodegeneration](/mechanisms/microglial-activation-neurodegeneration) — Mechanism page for microglial pathology
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-mechanisms-comparison) — Mechanism page for inflammatory pathways
References
[Boncoeur et al., YKL-40 in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34065781/)
[Olsson et al., YKL-40 in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30628743/)
[Schmidt et al., YKL-40 and neuroinflammation in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35263569/)
[Matczak et al., YKL-40 in CSF from AD and MS patients (2012)](https://pubmed.ncbi.nlm.nih.gov/22209124/)
[Corell et al., YKL-40 in progressive MS (2018)](https://pubmed.ncbi.nlm.nih.gov/29574776/)
[Beyer et al., YKL-40 in ALS CSF (2019)](https://pubmed.ncbi.nlm.nih.gov/30989443/)
[Huang et al., YKL-40 in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35416485/)
[Victor et al., YKL-40 and neuroinflammation imaging (2021)](https://pubmed.ncbi.nlm.nih.gov/34426581/)
[Comabella et al., YKL-40 in multiple sclerosis (2010)](https://pubmed.ncbi.nlm.nih.gov/21061395/)
[Karlsen et al., YKL-40 in FTD spectrum (2019)](https://pubmed.ncbi.nlm.nih.gov/31201475/)
[Jensen et al., YKL-40 and microglial activation (2013)](https://pubmed.ncbi.nlm.nih.gov/24330368/)
[Connor et al., YKL-40 CSF in healthy aging (2020)](https://pubmed.ncbi.nlm.nih.gov/31816449/)
[Sutphen et al., YKL-40 as biomarker for AD progression (2022)](https://pubmed.ncbi.nlm.nih.gov/36239936/)
[Brugge et al., YKL-40 in rodent models of neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/30993878/)
[Hooton et al., YKL-40 in DLB and PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37376951/)
[Chen et al., YKL-40 in traumatic brain injury (2020)](https://pubmed.ncbi.nlm.nih.gov/31684766/)
[Zhang et al., YKL-40 in ALS progression (2023)](https://pubmed.ncbi.nlm.nih.gov/37342244/)